NURSE OWNED AND OPERATED
OLIVE'S BRANCH does NOT distribute medicine
Copyright © Olive's Branch 2019
I receive several healthcare/medical newsletters and association updates into my inbox daily. I am always interested in reading about the latest and greatest compounds being developed in our crusade against disease and illness.
Today's big news came from the FDA and its approval of a combination therapy to treat melanoma.
Per the article, the combination immunotherapy regimen was associated with a median progression-free survival of 8.9 months versus 4.7 months for ipilimumab alone, Bristol-Myers Squibb reported and serious adverse reactions occurred in 62% versus 39% of patients taking the combination and monotherapy, respectively. (1)
New drug combination has reported a >20% increase in serious adverse reactions
New drug combination can potentially increase your life by 18 weeks
I look forward to the day when we see cannabinoids used in conjunction with immunotherapy and/or standard chemotherapy treatments improving patient outcomes and overall survival.
Until that time, anecdotal evidence is all we have.